To demonstrate the safety and feasibility of 2-fraction stereotactic body radiation therapy (SBRT) for prostate cancer. This single-center, noncomparative, phase 2/R-IDEAL 2b trial randomized 46 patients with intermediate/lower high-risk prostate cancer with visible gross tumor volume on multiparametric magnetic resonance imaging to receive 36.25 Gy in 5 fractions over 10 days or 24 Gy in 2 fractions with a gross tumor volume boost up to 27 Gy over 8 days. All treatment was delivered on a magnetic resonance linac with daily adaptive replanning. The primary endpoint was acute grade ≥2 (G2+) genitourinary (GU) toxicity (Common Terminology Criteria for Adverse Events version 5.0). Secondary endpoints include gastrointestinal (GI) toxicity and patient-reported outcomes. G2+ GU acute toxicity was observed in 6 of 22 patients (27.3%; 95% CI, 0.11-0.50) in the 2-fraction group and 7 of 24 patients (29.2%; 95% CI, 0.13-0.50) in the 5-fraction group. There were no grade 3 GU toxicities. G2+ urinary frequency rose from 4.5% (1 of 22) at week 2 to 13.6% (3 of 22) at week 4 in 2-fraction SBRT. G2+ urinary frequency peaked earlier in 5-fraction SBRT at 16.7% (4 of 24) in week 2, falling to 12.5% (3 of 24) at week 4. At 12 weeks, median Expanded Prostate Cancer Index Composite-26 urinary incontinence score was 85.5 (IQR, 75-100) for 2-fraction SBRT and 100 (IQR, 93.8-100) for 5-fraction SBRT. Urinary irritative-obstructive scores were higher at 12 weeks in the 2-fraction group (93.8; IQR, 87.5-100) than in the 5-fraction group (87.5; IQR, 81.3-93.8). Peak International Prostate Symptoms Score was lower in the 2-fraction group (8; IQR, 4-11) than in the 5-fraction group (13.5; IQR, 10-17). G2+ GI acute toxicity occurred in 3 of 24 (6.8%) after 5-fraction SBRT, but none after 2-fraction SBRT. Acceptable acute GU toxicity was seen after 2-fraction SBRT. Acute GI toxicity was low. Randomized trials are warranted to explore late toxicity and biochemical control.
Stereotactic body radiotherapy (SBRT) is effective for localised prostate cancer but increases genitourinary adverse events (AE). Focal boost to the dominant lesion may improve disease control. The DESTINATION study investigates whole gland dose de-escalation, with focal boost, using MR-guided adaptive radiotherapy (MRgART), to maintain cancer control whilst demonstrating acceptable AE. DESTINATION is a prospective, phase II federated study that enrolled men with localised prostate cancer across three institutions (The Royal Marsden Hospital, Sunnybrook Health Sciences Centre, and The Netherlands Cancer Institute). Patients received MRgART with daily online replanning to deliver 30 Gy in 5 fractions to the whole prostate with no margin. The gross tumour volume (GTV) + 4 mm intra-prostatic margin received an isotoxic boost of 45 Gy. Acute AE were assessed using CTCAEv5 at baseline, end of treatment, 4 weeks, and 12 weeks post-treatment. Patient-reported outcomes were collected using IPSS, EPIC-26 and IIEF5. All 60 patients completed 12-weeks follow-up. Grade 2 genitourinary AE occurred in 55 % of patients by 12 weeks. Grade 2 gastrointestinal AE occurred in 11.7 %. Patient-reported outcomes demonstrated expected symptom flare at final fraction of treatment followed by gradual recovery. EPIC scores were consistently higher at NKI compared to RMH/SB, with sexual function decline during follow-up across all centres. The DESTINATION study demonstrates that dose de-escalation 5-fraction SBRT with isotoxic focal boost produces acute AE rates similar to or above the levels seen in the PACE-B trial. The focal boost may have offset any potential decrease in AE from whole gland de-escalation.
2 April 2025 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
InPACT addresses the optimal management of locally advanced penile cancer, aiming to prospectively evaluate the relative benefits and sequencing of surgery, chemotherapy, and chemoradiotherapy. At trial inception, radiation therapy protocols for this rare cancer lacked consistency and standardization, necessitating multicenter, international collaboration to develop comprehensive radiation therapy planning, delivery, and quality assurance guidelines. InPACT has 2 main aims; to establish the efficacy of neoadjuvant chemotherapy or chemoradiotherapy in patients with macroscopically-involved inguinal nodes. Second, to compare prophylactic pelvic lymph node dissection plus chemoradiation to the inguinal and pelvic fields versus chemoradiation alone in patients whose inguinal node histology predicts a high risk of occult pelvic node involvement. The primary outcome measure for the trial is survival time. An international group was convened to achieve consensus on radiation therapy contouring, planning, dose, fractionation, and delivery for this rare cancer. These guidelines have been used throughout the conduct of the trial to date and form part of the radiation therapy quality assurance for each participating center. International consensus radiation therapy guidelines were established, encompassing risk status assessment and indications for each treatment region based on radiological and pathologic risk status of nodal basins. Guidance provides a nodal contouring atlas, addresses prepubic fat coverage, and specifies dose fractionation for both neoadjuvant and adjuvant settings, including recommendations for macroscopic disease. Trial recruitment is ongoing. Oncological and toxicity outcomes will be reported in due course. The InPACT radiation therapy guidelines offer a step toward international consensus on contouring for inguino-pelvic radiation therapy in penile cancer.
Background/Objectives: Advancements in radiotherapy technology now enable the delivery of ablative doses to targets in the upper urinary tract, including primary renal cell carcinoma (RCC) or upper tract urothelial carcinomas (UTUC), and secondary involvement by other histologies. Magnetic resonance imaging-guided linear accelerators (MR-Linacs) have shown promise to further improve the precision and adaptability of stereotactic body radiotherapy (SBRT). Methods: This single-institution retrospective study analyzed 34 patients (31 with upper urinary tract non-metastatic primaries [RCC or UTUC] and 3 with metastases of non-genitourinary histology) who received SBRT from August 2020 through September 2024 using a 1.5 Tesla MR-Linac system. Treatment plans were adjusted by using [online settings] for “adapt-to-position” (ATP) and “adapt-to-shape” (ATS) strategies for anatomic changes that developed during treatment; compression belts were used for motion management. Results: The median duration of treatment was 56 min overall and was significantly shorter using the adapt-to-position (ATP) (median 54 min, range 38–97 min) in comparison with adapt-to-shape (ATS) option (median 80, range 53–235 min). Most patients (77%) experienced self-resolving grade 1–2 acute radiation-induced toxicity; none had grade ≥ 3. Three participants (9%) experienced late grade 1–2 toxicity, potentially attributable to SBRT, with one (3%) experiencing grade 3. Conclusions: We conclude that MR-Linac-based SBRT, supported by online plan adaptation, is a feasible, safe, and highly precise treatment modality for the definitive management of select upper urinary tract lesions.
Deep learning (DL) models have been widely proposed to automate MRI-based delineation, but their use is hindered by differences in image characteristics between training and evaluation datasets (i.e. domain shift). This paper aims to (i) analyse the impacts of different sources of domain shift and (ii) externally evaluate a model trained using heterogeneous public data and compare it with an in-house model. The nnU-Net DL framework was trained for prostate autocontouring using axial T2-weighted (T2W) prostate MRIs from five public datasets. By controlling training set size, three sources of domain shift were evaluated: dataset, scanner vendor/field strength, and image acquisition/annotation protocol. 66 prostate MRIs were used for external evaluation and training/evaluation of an in-house model. The Dice Similarity Coefficient (DSC) and 95 % Hausdorff distance (HD) evaluated the model-produced contours. The performance gap (Δ) between intra/inter-domain evaluation showed that domain shift from scanner vendor/field strength (ΔDSC = 0.33, Δ95 % HD = 246.86 mm) and image acquisition/annotation protocols (ΔDSC = 0.20, Δ95 % HD = 14.70 mm) had greater impact than that from dataset (ΔDSC = 0.06, Δ95 % HD = 3.69 mm), although all were significant (p < 0.05). External evaluation showed that the mixed-domain trained model performed well but was less robust than the in-house model (median (IQR) DSC/95 % HD = 0.87 (0.06)/3.75 (4.47)mm, 0.90 (0.03)/1.03 (1.29) mm, p < 0.05, respectively). We highlight for the first time the domain shift effect of image acquisition/annotation protocol, even with images acquired using the same scanner vendor/field strength. Understanding the effect of multiple sources of domain shift has enabled us to train a robust model that can be safely clinically deployed.
Simulation-free radiotherapy offers improved efficiency for adaptive treatments. This planning study presents a simulation-free pre-treatment workflow for prostate cancer online adaptive radiotherapy on a MR-Linac. Previously acquired diagnostic MR images are used to create a reference treatment plan without clinician input, and adapted plans are then simulated, and compared with those from the traditional workflow. All patients treated with 36.25 Gy in 5-fractions within the HERMES trial were retrospectively assessed for eligibility of simulation-free reference planning. If eligible, reference images were created from existing diagnostic MRI (T1w and T2w) to enable MR-only reference treatment planning. Target and OAR reference structures were autosegmented without clinician input. Online plan adaptation was simulated using existing clinical treatment images and structure sets. Adapted plans were compared with existing clinical plans, and synthetic CT accuracy assessed. 87.5 % of patients had suitable diagnostic scans. Reference images and treatment plans were successfully created. Online treatment plans were simulated and were clinically acceptable for target dose and conformality, meeting all mandatory clinical goals with no detriment to OAR dose or plan deliverability. Accuracy of the synthetic CT approach was high with gamma results at 2mm/2% all above 98.9 %. This study has shown that non radiotherapy-dedicated diagnostic MRI can be used for reference prostate planning on the MR-Linac, generating clinically equivalent adapted plans when compared to those originating from radiotherapy-simulation reference plans. This potentially saves multiple weeks in the pathway, improving radiotherapy efficiency and patient experience.